Changes in the Intestinal Microbiota of Patients with Inflammatory Bowel Disease with Clinical Remission during an 8-Week Infliximab Infusion Cycle

Changes in the Intestinal Microbiota of Patients with Inflammatory Bowel Disease with Clinical Remission during an 8-Week Infliximab Infusion Cycle

This study investigated changes in the intestinal microbiota during 8-week infliximab maintenance therapy in inflammatory bowel disease (IBD) patients in clinical remission. Microbial compositional differences were analyzed according to the trough level of infliximab (TLI) and mucosal healing (MH) s...

Full description

Bibliographic Details
Main Authors:	Gyeol Seong, Namil Kim, Je-Gun Joung, Eun Ran Kim, Dong Kyung Chang, Jongsik Chun, Sung Noh Hong, Young-Ho Kim
Format:	Article
Language:	English
Published:	MDPI AG 2020-06-01
Series:	Microorganisms
Subjects:	inflammatory bowel disease intestinal microbiota infliximab mucosal healing
Online Access:	https://www.mdpi.com/2076-2607/8/6/874

Similar Items

Early infliximab antibody testing does not prevent infusion reactions when reinitiating infliximab
by: Joseph D. Feuerstein
Published: (2016-08-01)

Inflammatory bowel disease of the lung: The role of infliximab?
by: Adam J. Hayek, et al.
Published: (2015-01-01)

Premedication Does Not Influence the Incidence of Infliximab Infusion Reactions in Pediatric Patients with Inflammatory Bowel Disease—A Single Center Case–Control Study
by: Edyta Szymanska, et al.
Published: (2021-07-01)

Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis
by: Elham A Hassan, et al.
Published: (2017-01-01)

Autoimmune hemolytic anemia associated with infliximab infusion in ulcerative colitis
by: Fazia A. Mir, et al.
Published: (2018-02-01)

Effect of infliximab therapy on serum and fecal biomarker levels in pediatric patients with inflammatory bowel disease
by: Ellis, Montana
Published: (2021)

Trough level of infliximab is useful for assessing mucosal healing in Crohn's disease: a prospective cohort study
by: Akihiro Koga, et al.
Published: (2018-04-01)

The Interplay between Mucosal Microbiota Composition and Host Gene-Expression is Linked with Infliximab Response in Inflammatory Bowel Diseases
by: Nikolas Dovrolis, et al.
Published: (2020-03-01)

Co-existence of relapsing polychondritis and Crohn disease treated successfully with infliximab
by: Hye-In Jung, et al.
Published: (2021-01-01)

Infusion reaction to infliximab biosimilar after transitioning from infliximab
by: Reem Kashlan, MPH, et al.
Published: (2021-02-01)

Study on the role of magnetic resonance enterography in valuating infliximab therapy in small bowel crohn’s disease
by: Li-Wei Dong, et al.
Published: (2019-12-01)

High body mass index is not associated with increased treatment failure in infliximab treated pediatric patients with inflammatory bowel disease
by: Isaac Rodin, et al.
Published: (2020-06-01)

Development of peripheral eosinophilia in inflammatory bowel disease patients on infliximab treated at a tertiary pediatric inflammatory bowel disease center is associated with clinically active disease but does not result in loss of efficacy or adverse outcomes
by: Douglas Zabrowski, et al.
Published: (2020-08-01)

High Serum Creatine Kinase Levels in Infliximab and Vedolizumab-Treated Inflammatory Bowel Disease Patients
by: Manuel Sutter, et al.
Published: (2021-08-01)

Acute Phase Reaction After Infliximab Infusion
by: Ozan Ünlü, et al.
Published: (2019-09-01)

Serum-Infliximab Trough Levels in 45 Children with Inflammatory Bowel Disease on Maintenance Treatment
by: Helena Rolandsdotter, et al.
Published: (2017-03-01)

Nanocomposites-based targeted oral drug delivery systems with infliximab in a murine colitis model
by: Jung Min Kim, et al.
Published: (2020-09-01)

Is safety infliximab during pregnancy in patients with inflammatory bowel disease? ¿El tratamiento con infliximab es seguro durante el embarazo en pacientes con enfermedad inflamatoria intestinal?
by: Federico Argüelles-Arias, et al.
Published: (2012-02-01)

Towards the Oral Treatment of Ileo-Colonic Inflammatory Bowel Disease with Infliximab Tablets: Development and Validation of the Production Process
by: Bahez Gareb, et al.
Published: (2019-08-01)

External Model Performance Evaluation of Twelve Infliximab Population Pharmacokinetic Models in Patients with Inflammatory Bowel Disease
by: Christina Schräpel, et al.
Published: (2021-08-01)

Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice
by: Tomoo Nakagawa, et al.
Published: (2019-10-01)

Peritoneal Tuberculosis during Infliximab Treatment in a Patient with Ulcerative Colitis Despite a Negative Quantiferon Test
by: Anna Colombo, et al.
Published: (2021-04-01)

Anti-Drug Antibodies in Patients with Inflammatory Bowel Diseases Treated with Biosimilar Infliximab: A Prospective Cohort Study
by: Anna Pękala, et al.
Published: (2021-06-01)

Multidrug-resistant Disseminated Tuberculosis Related to Infliximab in a Patient with Ulcerative Colitis and Negative Evaluation for Latent Tuberculosis
by: Yu Kyung Jun, et al.
Published: (2019-09-01)

Successful treatment with vedolizumab in an adolescent with Crohn disease who had developed active pulmonary tuberculosis while receiving infliximab
by: Sujin Choi, et al.
Published: (2021-07-01)

Uso de infliximabe na policondrite recidivante Infliximab in relapsing polychondritis
by: Ana Paula Soares de Barros, et al.
Published: (2010-04-01)

Infliximab and biosimilar infliximab in psoriasis: efficacy, loss of efficacy, and adverse events
by: Subedi S, et al.
Published: (2019-07-01)

Evaluation of efficacy and comparative frequency of adverse events in patients with ulcerative colitis receiving the original infliximab and its biosimilar. One year of observation
by: O V Knyazev, et al.
Published: (2019-08-01)

Refractory Duodenal Crohn's Disease Successfully Treated with Infliximab
by: You Lim Kim, et al.
Published: (2014-01-01)

SERUM INFLIXIMAB MEASUREMENT IN INFLAMMATORY BOWEL DISEASE PATIENTS IN REMISSION: A COMPARATIVE ANALYSIS OF TWO DIFFERENT METHODS IN A MULTICENTRIC BRAZILIAN COHORT
by: Fábio Vieira TEIXEIRA, et al.

Adoption of Biosimilar Infliximab for Rheumatoid Arthritis, Ankylosing Spondylitis, and Inflammatory Bowel Diseases in the EU5: A Budget Impact Analysis Using a Delphi Panel
by: Tim A. Kanters, et al.
Published: (2017-05-01)

Successful Treatment of Postoperative Fistula with Infliximab in a Patient with Crohn's Disease
by: Seong Yeon Jeong, et al.
Published: (2014-01-01)

Do plasticized polyvinylchloride and polyurethane infusion sets promote infliximab adsorption?
by: Chennell Philip, et al.
Published: (2020-05-01)

The Effect of Infliximab on Patients with Ulcerative Colitis in Korea
by: Hyun Il Seo, et al.
Published: (2014-07-01)

INFLIXIMAB AND TUMOUR NECROSIS FACTOR ALPHA MEASUREMENT ON INTESTINAL MUCOSA: A NEW TOOL FOR THE CLINIC?
by: Silvia Pecere, et al.
Published: (2016-12-01)

Evaluation of the safety and satisfaction of rheumatic patients with accelerated infliximab infusion
by: Jozélio Freire de Carvalho, et al.
Published: (2018-08-01)

Infliximab induces clinical, endoscopic and histological responses in refractory ulcerative colitis Infliximab induce respuesta clínica, endoscópica e histológica en la colitis ulcerosa refractaria
by: F. Bermejo, et al.
Published: (2004-02-01)

Tratamento com infliximabe da doença de Behçet ativa Therapy with infliximab in active Behçet's disease
by: Alexandre Wagner Silva de Souza, et al.
Published: (2005-04-01)

Bronchopulmonary lesions in chronic inflammatory bowel diseases
by: Zyfa Fyaskhetdinovna Mikhaylova, et al.
Published: (2010-03-01)

ADALIMUMAB INDUCTION AND MAINTAINING REMISSION FOR CROHN’S DISEASE IN PATIENT WHO LOST RESPONSE TO INFLIXIMAB. Case report
by: Ivaylo Vazharov, et al.
Published: (2016-12-01)